Genethon III – Vector Study Pioneers
The mission of Genethon III was to develop tools for delivering therapeutic genes in a therapeutic setting.
Under the scientific management of Olivier Danos, Genethon concentrated on researching, developing and manufacturing gene therapy vectors: AAV (adeno-associated virus), and retroviral and lentiviral vectors.
Its primary goal was to provide quality vectors for preclinical animal studies for the whole of the scientific community.
Its second aim was to develop the best possible procedures for producing vectors for human use.
Genethon III eventually produced 3,000 batches of vectors that were used for preclinical studies within the GVPN (Gene Vector Production Network).